trial · primary record
Bevacizumab
Ras-mutated Metastatic Colorectal Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2030-04-30 |
| Primary endpoint | Overall Response Rate (ORR) |
| Registry ID | NCT07446322 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:14.589Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07446322
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.